The AI-based clinical trial solutions market size is estimated to be USD 235.21 million in 2022 and is expected to witness a CAGR of 27.21% during the forecast period 2023-2033. The adoption of AI-powered solutions in managing and performing clinical trials, growing government activities to encourage the use of artificial intelligence (AI) technologies in the healthcare industry, rising healthcare expenditure by major players, and growing public awareness of AI-based technology are projected to drive the market growth in near future. However, issues associated with data privacy is predicted to limit market growth.

Growing government activities to encourage the use of artificial intelligence (AI) technologies in the healthcare industry is expected to drive the market growth. Government entities in industrialised countries such as U.S. and Europe are funding the development of AI-based clinical trial study solutions even while establishing a strict regulatory framework. Additionally, developing country governments are training stakeholders about AI-based clinical trial solutions so that they may concentrate on finding novel treatments and expediting patient enrollment, which will increase patient engagement and monitoring.

Rising healthcare expenditure by major players is projected to propel the market growth. Healthcare IT expenditures account for a sizable portion of healthcare costs in developed nations. Countries are implementing AI-based solutions to lower expenses and boost productivity. For instance, in September 2022, the National Institutes of Health (NIH) launched the Bridge2AI project, which will include participants from many organizations and focus on developing various tools, resources, and data for developing an AI strategy.

Segmentation

By Therapeutic Application

The market is categorized into cardiovascular diseases, infectious diseases, metabolic diseases, oncology, neurological diseases, and others. In 2022, the oncology segment accounted for the highest revenue share due to the rising prevalence of cancer worldwide. Leading pharmaceutical corporations are collaborating with AI development company to deploy AI-based oncology technologies designed for the development of pharmaceuticals. For instance, a collaboration between Deep Lens and Hematology-Oncology Associates of Central New York in January 2022 will be centred on the extension of the medical trial program’s clinical trial programs. By pre-screening all patients, the VIPER by Deep Lens will be used to categorize the patients who are qualified for clinical trials. Growth in the segment is further driven by the introduction of new technologies. For instance, Survivor Net introduced an AI-based clinical trial locator in June 2022 that connects individuals with cancer who are in need with advanced cancer research.

By End User

The market is categorized into academia, pharmaceutical companies, and others. In the global market, pharmaceutical companies the segment accounted for the largest revenue share in 2022 owing to increasing emphasis on developing biomarkers and diagnostics. For instance, text mining system Linguamatics from IQVIA offers NLP-based solutions for pharmaceutical companies. The pharmaceutical industry is expanding as a result of the rising prevalence of chronic diseases and the increase in demand for customized therapy. The market is also benefitting from a partnership between major pharmaceutical companies and AI providers for the implementation of AI technology designed for the complete medicine development process. However, it is anticipated that the others segment would have the fastest CAGR during the forecast period. The growth can be credited to the growing use of AI-based solutions by government entities and research organizations (CROs), as these solutions lower the cost of clinical trials by improving the quality of data, rising patient compliance & retention, and more precisely determining the efficacy of the treatment.

Regional Markets

In 2022, North America region accounted for the highest revenue in the AI-based clinical trial solutions market and is expected to maintain its dominance during the forecast period. This is attributed to existence of major companies in the area and increase in the number of start-ups using AI. Additionally, the region has a significant number of registered clinical studies, which benefits the industry. According to data from the World Health Organization (WHO), the United States conducted the most clinical trials, approximately 157,618 trials, between 1999 and 2021. The region’s growth is further spurred by the increasing government schemes for the use of AI-based technologies and the rising preference in these technologies. However, the Asia Pacific region is anticipated to exhibit the market’s quickest CAGR during the forecast period as a result of rising adoption of clinical technologies based on AI, increasing number of clinical studies, and government efforts.

Competitor Insights

Some of the key players operating in the AI-based clinical trial solutions market are AmerisourceBergen Corporation, Aris Global, Antidote Technologies, Inc., Deep Lens, Unlearn.AI, Inc., Deep6.ai, Koneksa, Microsoft Corporation, Mendel.ai, and GNS Healthcare.

To achieve a competitive edge, these companies are implementing a variety of growth strategies. Strategic partnerships, alliances, and agreements with different businesses and research institutions are seen to be the main strategies used by companies in this sector.

• For instance, Deep Lens AI and Oregon Oncology Specialists entered into a strategic partnership in April 2021 to deploy a Deep Lens AI-powered clinical trial solution for identifying individuals who are eligible for clinical trial trials.

This comprehensive research report focuses on the global and regional market size and forecasts of diverse segments including therapeutic application and end user from 2022 to 2033.

Report Scope:

Segmentation: AI-based Clinical Trial Solutions for Patient Matching Market Report 2022 – 2033

Therapeutic Application (Revenue, USD Million), 2022 – 2033

• Cardiovascular Diseases
• Infectious Diseases
• Metabolic Diseases
• Oncology
• Neurological Diseases
• Others

End user (Revenue, USD Million), 2022 – 2033

• Academia
• Pharmaceutical Companies
• Others

By Region (Revenue, USD Million), 2022 – 2033

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of APAC
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of LATAM
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Rest of MEA